Press release
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PD-1 and PD-L1 Inhibitors pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."PD-1 and PD-L1 Inhibitors Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 and PD-L1 Inhibitors Market.
The PD-1 and PD-L1 Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report:
*
Companies across the globe are diligently working toward developing novel PD-1 and PD-L1 Inhibitors treatment therapies with a considerable amount of success over the years.
*
PD-1 and PD-L1 Inhibitors companies working in the treatment market are Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others, are developing therapies for the PD-1 and PD-L1 Inhibitors treatment
*
Emerging PD-1 and PD-L1 Inhibitors therapies such as - CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others are expected to have a significant impact on the PD-1 and PD-L1 Inhibitors market in the coming years.
*
In May 2025, Clinical-stage biopharma company OmRx Oncology (OmRx) has launched a randomized Phase II trial for its oral PD-L1 inhibitor, OX-4224, aimed at patients with non-small cell lung cancer (NSCLC). The company believes this investigational small molecule could provide a more affordable and accessible alternative to current antibody-based treatments. The open-label study plans to enroll around 50 metastatic NSCLC patients, primarily in India, who have not previously received immune checkpoint inhibitor therapies. OX-4224 will be assessed as a second-line monotherapy in this patient population.
*
In March 2025, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, has announced a new clinical program featuring trials of Actimab-A combined with either KEYTRUDA Registered (pembrolizumab) or OPDIVO Registered (nivolumab). These blockbuster PD-1 inhibitors, developed by Merck & Co. and Bristol Myers Squibb respectively, together generated $38.8 billion in sales in 2024 across multiple solid tumor indications. Despite their success, their effectiveness is often limited by Myeloid Derived Suppressor Cells (MDSCs), which accumulate in the tumor microenvironment and express the CD33 antigen - the specific target of Actimab-A. The trials aim to explore whether depleting MDSCs with Actimab-A can enhance the efficacy of these immunotherapies.
*
In January 2025, ImmunityBio, Inc. (NASDAQ: IBRX) announced a new collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company, to conduct a pivotal randomized Phase 3 trial (ResQ201A-NSCLC). This trial will combine BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln). The ResQ201A-NSCLC study (NCT06745908) aims to validate the efficacy and safety of this combination, previously shown in the QUILT 3.055 trial, and provide evidence that these two immunotherapies can enhance overall survival in patients with advanced or metastatic NSCLC who have developed resistance to immune CPI treatments.
PD-1 and PD-L1 Inhibitors Overview
PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells and eliminate them before they can turn into cancer
Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape [https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging PD-1 and PD-L1 Inhibitors Drugs Under Different Phases of Clinical Development Include:
*
CTX-8371: Compass Therapeutics
*
CA 327: Aurigene Discovery Technologies
*
RC-98: RemeGen
*
AUR-106: Aurigene Discovery Technologies
*
INBRX 105: Inhibrx
*
Tomivosertib: Effector Therapeutics
*
CX-072: CytomX Therapeutics
*
IBI 323: Innovent Biologics
*
Jemperli: GlaxoSmithKline
*
BCD-100: Biocad
*
TECENTRIQ: Genentech
*
Opdivo: Bristol Myers Squibb
*
KEYTRUDA: Merck
PD-1 and PD-L1 Inhibitors Pipeline Therapeutics Assessment
*
PD-1 and PD-L1 Inhibitors Assessment by Product Type
*
PD-1 and PD-L1 Inhibitors By Stage and Product Type
*
PD-1 and PD-L1 Inhibitors Assessment by Route of Administration
*
PD-1 and PD-L1 Inhibitors By Stage and Route of Administration
*
PD-1 and PD-L1 Inhibitors Assessment by Molecule Type
*
PD-1 and PD-L1 Inhibitors by Stage and Molecule Type
DelveInsight's PD-1 and PD-L1 Inhibitors Report covers around 200+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further PD-1 and PD-L1 Inhibitors product details are provided in the report. Download the PD-1 and PD-L1 Inhibitors pipeline report to learn more about the emerging PD-1 and PD-L1 Inhibitors therapies [https://www.delveinsight.com/sample-request/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the PD-1 and PD-L1 Inhibitors Therapeutics Market include:
Key companies developing therapies for PD-1 and PD-L1 Inhibitors are - F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, Others.
PD-1 and PD-L1 Inhibitors Pipeline Analysis:
The PD-1 and PD-L1 Inhibitors pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 and PD-L1 Inhibitors with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 and PD-L1 Inhibitors Treatment.
*
PD-1 and PD-L1 Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
PD-1 and PD-L1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 and PD-L1 Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors drugs and therapies [https://www.delveinsight.com/sample-request/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
PD-1 and PD-L1 Inhibitors Pipeline Market Drivers
*
Rise in prevalence of Cancer, PD-1 and PD-L1 Inhibitors are emerging as an important checkpoint inhibitors used as frontline treatment in various cancer are some of the important factors that are fueling the PD-1 and PD-L1 Inhibitors Market.
PD-1 and PD-L1 Inhibitors Pipeline Market Barriers
*
However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the PD-1 and PD-L1 Inhibitors Market growth.
Scope of PD-1 and PD-L1 Inhibitors Pipeline Drug Insight
*
Coverage: Global
*
Key PD-1 and PD-L1 Inhibitors Companies: Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others
*
Key PD-1 and PD-L1 Inhibitors Therapies: CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others
*
PD-1 and PD-L1 Inhibitors Therapeutic Assessment: PD-1 and PD-L1 Inhibitors current marketed and PD-1 and PD-L1 Inhibitors emerging therapies
*
PD-1 and PD-L1 Inhibitors Market Dynamics: PD-1 and PD-L1 Inhibitors market drivers and PD-1 and PD-L1 Inhibitors market barriers
Request for Sample PDF Report for PD-1 and PD-L1 Inhibitors Competitive Assessment and clinical trials [https://www.delveinsight.com/sample-request/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
PD-1 and PD-L1 Inhibitors Report Introduction
2
PD-1 and PD-L1 Inhibitors Executive Summary
3
PD-1 and PD-L1 Inhibitors Overview
4
PD-1 and PD-L1 Inhibitors- Analytical Perspective In-depth Commercial Assessment
5
PD-1 and PD-L1 Inhibitors Pipeline Therapeutics
6
PD-1 and PD-L1 Inhibitors Late Stage Products (Phase II/III)
7
PD-1 and PD-L1 Inhibitors Mid Stage Products (Phase II)
8
PD-1 and PD-L1 Inhibitors Early Stage Products (Phase I)
9
PD-1 and PD-L1 Inhibitors Preclinical Stage Products
10
PD-1 and PD-L1 Inhibitors Therapeutics Assessment
11
PD-1 and PD-L1 Inhibitors Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
PD-1 and PD-L1 Inhibitors Key Companies
14
PD-1 and PD-L1 Inhibitors Key Products
15
PD-1 and PD-L1 Inhibitors Unmet Needs
16
PD-1 and PD-L1 Inhibitors Market Drivers and Barriers
17
PD-1 and PD-L1 Inhibitors Future Perspectives and Conclusion
18
PD-1 and PD-L1 Inhibitors Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-and-pdl1-inhibitors-competitor-landscape-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-compass-therapeutics-aurigene-discovery-tech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech here
News-ID: 4070650 • Views: …
More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…

Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…

Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Inhibitors
Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826
This latest report researches the industry structure,…
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market.
CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155
The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to…
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4…
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.
The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab…